Literature DB >> 24795036

Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model.

Samjhana Thapaliya1, Alexander Wree, Davide Povero, Maria Eugenia Inzaugarat, Michael Berk, Laura Dixon, Bettina G Papouchado, Ariel E Feldstein.   

Abstract

BACKGROUND/AIMS: Hepatocyte cell death is a key feature of nonalcoholic steatohepatitis (NASH). As the contribution of specific caspases remains unclear, our aim was to ascertain the effect of caspase 3 suppression on liver injury and fibrogenesis.
METHODS: C57BL/6 wild-type (WT) and caspase 3 knock out (Casp3 (-/-)) mice were placed on a methionine- and choline-deficient (MCD) diet for 6 weeks to induce steatohepatitis and liver fibrosis. Thereafter, liver injury, liver fibrosis and hepatocellular apoptosis were quantified in liver sections. Additionally, expression of proteins associated with liver inflammation and fibrogenesis was analyzed.
RESULTS: WT mice fed MCD diet showed marked activation of caspase 3 in hepatocytes, in conjunction with steatohepatitis and increased hepatic triglyceride levels, hepatocyte ballooning, inflammation and fibrosis. Casp3 (-/-) mice fed the MCD diet showed similar serum aminotransferase levels and NAFLD activity scores (NAS) compared with WT MCD-fed mice. However, Casp3 (-/-) mice on the MCD diet showed a marked reduction in expression of transcripts for profibrogenic genes, which translated into reduced hepatic collagen deposition. These changes were associated with decreased levels of apoptosis, and a significant reduction in the expression of cytokines involved in inflammatory signaling. Casp3 (-/-) mice on the MCD showed a reduction in expression of chemokine receptor 2 (CCR2) leading to ameliorated infiltration of inflammatory lymphocyte antigen 6 complex, locus C1 (Ly6c) positive monocytes.
CONCLUSION: These findings support a prominent role for hepatocyte caspase 3 activation in NASH-related apoptosis, fibrogenesis and fibrosis which in part is mediated via CCR2-dependent infiltration of Ly6c positive monocytes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24795036      PMCID: PMC4512760          DOI: 10.1007/s10620-014-3167-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  40 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Steatohepatitis and apoptosis: therapeutic implications.

Authors:  Ariel Feldstein; Gregory J Gores
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

Review 3.  Animal models of steatosis.

Authors:  A Koteish; A M Diehl
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

Review 4.  Nonalcoholic fatty liver disease in the pediatric population: a review.

Authors:  Anna Wieckowska; Ariel E Feldstein
Journal:  Curr Opin Pediatr       Date:  2005-10       Impact factor: 2.856

Review 5.  Apoptosis in alcoholic and nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Gregory J Gores
Journal:  Front Biosci       Date:  2005-09-01

6.  Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats.

Authors:  Michio Imamura; Tadashi Ogawa; Yasuyuki Sasaguri; Kazuaki Chayama; Hikaru Ueno
Journal:  Gastroenterology       Date:  2005-01       Impact factor: 22.682

7.  Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis.

Authors:  Naim Alkhouri; Agnieszka Gornicka; Michael P Berk; Samjhana Thapaliya; Laura J Dixon; Sangeeta Kashyap; Philip R Schauer; Ariel E Feldstein
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

8.  Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway.

Authors:  Ariel E Feldstein; Nathan W Werneburg; Ali Canbay; Maria Eugenia Guicciardi; Steven F Bronk; Robert Rydzewski; Laurence J Burgart; Gregory J Gores
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

Review 9.  Caspases - an update.

Authors:  Indrajit Chowdhury; Binu Tharakan; Ganapathy K Bhat
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2008-07-03       Impact factor: 2.231

10.  The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity.

Authors:  ZhengZheng Li; Michael Berk; Thomas M McIntyre; Gregory J Gores; Ariel E Feldstein
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

View more
  30 in total

1.  Simultaneous deletion of Bax and Bak is required to prevent apoptosis and interstitial fibrosis in obstructive nephropathy.

Authors:  Hee-Seong Jang; Babu J Padanilam
Journal:  Am J Physiol Renal Physiol       Date:  2015-07-15

Review 2.  Immunoregulation by lipids during the development of non-alcoholic steatohepatitis.

Authors:  Pierluigi Ramadori; Daniela Kroy; Konrad L Streetz
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

Review 3.  Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.

Authors:  Manoela Mota; Bubu A Banini; Sophie C Cazanave; Arun J Sanyal
Journal:  Metabolism       Date:  2016-03-03       Impact factor: 8.694

Review 4.  Apoptosis and necroptosis in the liver: a matter of life and death.

Authors:  Robert F Schwabe; Tom Luedde
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

Review 5.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

6.  Protective effects of Phyllanthus emblica against myocardial ischemia-reperfusion injury: the role of PI3-kinase/glycogen synthase kinase 3β/β-catenin pathway.

Authors:  Mahesh Thirunavukkarasu; Vaithinathan Selvaraju; Leonidas Tapias; Juan A Sanchez; J Alexander Palesty; Nilanjana Maulik
Journal:  J Physiol Biochem       Date:  2015-09-05       Impact factor: 4.158

7.  Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis.

Authors:  Akiko Eguchi; Xavier De Mollerat Du Jeu; Casey D Johnson; Andronikou Nektaria; Ariel E Feldstein
Journal:  J Hepatol       Date:  2015-11-07       Impact factor: 25.083

8.  Caspases in metabolic disease and their therapeutic potential.

Authors:  Claire H Wilson; Sharad Kumar
Journal:  Cell Death Differ       Date:  2018-05-09       Impact factor: 15.828

9.  An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.

Authors:  Peng Zhao; Xiaoli Sun; Cynthia Chaggan; Zhongji Liao; Kai In Wong; Feng He; Seema Singh; Rohit Loomba; Michael Karin; Joseph L Witztum; Alan R Saltiel
Journal:  Science       Date:  2020-02-07       Impact factor: 47.728

10.  Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis.

Authors:  Li-Ya Mu; Shu-Qin Li; Li-Xin Tang; Rui Li
Journal:  Clinics (Sao Paulo)       Date:  2021-06-14       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.